The history of copyright's flagship drug presents a interesting case for stakeholders in the drug sector. While initially a phenomenal success, creating vast sums, the exclusivity lapse and the subsequent entry of cheaper competitors have considerably changed revenue. This poses questions about the ongoing profitability of analogous therapeutic pro